The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Nine years after diagnosis, 9.3 percent of U.S. cancer survivors were current smokers and 83 percent of these individuals were daily smokers who averaged 14.7 cigarettes per day, according to a study performed by researchers at the American Cancer Society.
Based on progression-free survival data, a single-arm, open-label phase IIa study of Asonep in metastatic renal cell carcinoma will be extended to a second cohort.
The phase III FOCUS clinical trial of Kyprolis in multiple myeloma did not meet its primary endpoint of improving overall survival.
A report from an international working group of researchers suggests that the process of evaluating human papillomavirus vaccines can be significantly shortened.
Genomic analyses of tissues from mantle cell lymphoma patients helped researchers explain two types of drug resistance and ways to overcome them in the clinic.
A phase III trial of Nexavar tablets in patients with advanced breast cancer did not meet its primary endpoint of extending progression-free survival.
Researchers with The Cancer Genome Atlas Network found that stomach cancers fall into four distinct molecular subtypes.
A phase III trial of Arzerra as a maintenance therapy for chronic lymphocytic leukemia met its primary endpoint of extending progression-free survival at an interim analysis.
FDA approved Zydelig (idelalisib) tablets for the treatment of three B-cell blood cancers.
